Albany, NY -- (SBWIRE) -- 12/03/2018 -- DelveInsight has announced the addition of the "Chronic Inflammatory Demyelinating Polyneuropath (CIDP) Market Insights, Epidemiology and Market Forecast- 2027 " drug pipelines to their offering.

The report provides an overview of the disease and market size of CIDP for the seven major markets i.e., the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the overview, treatment practice and forecasted epidemiology of CIDP from 2018 to 2027 segmented by seven major markets.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare neurological disorder that can cause progressive weakness, numbness and pain in the nerves. The disease is characterized by the inflammation of the nerve roots and peripheral nerves accompanied by destruction of myelin sheath (fatty protective covering) over the nerves. It is caused by the body's immune system inappropriately reacting against and damaging myelin. Other symptoms of CIDP include fatigue, burning, pain, clumsiness, difficulty swallowing and double vision. Although CIDP can occur at any age and in both genders, CIDP is more common in young adults, and more in men than women.

As per the National Organization for Rare Disorders, CIDP affects males twice as often as females (M2:F1) and the average age of onset is 50. According to American Association of Neuromuscular & Electrodiagnostic Medicine, the incidence of CIDP each year is estimated to be between 1.5 and 3.6 million in the US population.
As per DelveInsight's estimates, the prevalent cases of CIDP in the 7MM were 46,351 in 2016 and are estimated to increase by 2027. According to DelveInsight, the incidence of CIDP was found to be highest in the United States compared to the EU5 and Japan in 2016. In 2016, there were around 6,477 CIDP cases in USA. These cases are expected to increase during the forecast period. As per DelveInsight, in Japan, there were 610 total incident cases of CIDP and these are estimated to increase by 2027. In 2016, the highest prevalence was shown in age group of 61-70 in the US with 9,633 cases.

Geography Covered
1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027

CIDP Drug Companies
1. Baxalta
2. Octapharma
3. Kedrion Biopharma
4. Grifols
And many others

Drugs covered
1. HYQVIA
2. NewGam
3. Gammaked
4. Gamunex-C
And many others

Report Scope

The report covers the descriptive overview of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) explaining its pathophysiology, disease classification, diagnostic approaches and treatment algorithm. The report provides the insight into the epidemiology of the disease and its treatment in the 7 MM covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan. The report is a comprehensive account of both the current and emerging therapies covering the impact of the new therapies on the current treatment landscape. The report also reviews the detailed historical and forecasted CIDP market size covering the drug outreach in 7MM. The report provides the understanding of the future competition in CIDP by reviewing the market drivers and barriers.